

First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans

December 22, 2022

LAVAL, QC / December 22, 2022 / Bausch Health Companies Inc. (NYSE/TSX: BHC) and its Canadian dermatology division, one of the largest prescription dermatology health care businesses in Canada, today announced that its new topical prescription treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045% w/w), is now available to patients through the provincial public drug plans of Quebec, Ontario, Alberta and Saskatchewan, as well as the federal government's Non-Insured Health Benefits (NIHB) drug plan, which serves Canada's First Nations and Inuit populations.¹

ARAZLO is the first tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.² The listings by the four public drug plans are the first for ARAZLO in Canada, with others expected to follow as a result of the successful conclusion of listing negotiations with the panCanadian Pharmaceutical Alliance, representing the drug plans of the federal government and all provinces and territories.

"We are very pleased to have achieved agreements for these first public drug plan listings in Canada for ARAZLO," said Cees Heiman, Bausch Health, Senior Vice President, Europe and Canada. "It is an important further step in helping to provide new treatment options for the approximately 5.6 million Canadians who are impacted by acne."⁴ We are very proud to have a large dermatology portfolio to help meet Canadians' needs."

"While tazarotene is not a new retinoid, the vehicle in ARAZLO is a true innovation in topical technology and enhances the tolerability, and thus effectiveness, of this new product for acne patients," said Dr. Jerry Tan, MD, FRCPC, of Windsor, Ontario, President of the Acne and Rosacea Society of Canada, Adjunct Professor, Western University.

ARAZLO is the first tazarotene acne treatment available in a lotion formulated with PRISMATREX™ technology (formulation with known hydrating and moisturizing effects, which may alleviate dryness of skin)² and has been shown to provide a good tolerability profile. Retinoids like tazarotene are a core component of acne treatment. Providing the treatment in a lotion form helps limit the dryness and irritation that has historically been a barrier to the long-term use of tazarotene by patients.³

About Acne Vulgaris

Acne vulgaris ("vulgaris" means "common") is the most common skin problem seen by doctors in Canada. It occurs when the pores of the skin become plugged with oil and skin cells, often causing whiteheads, blackheads, pimples or cysts to appear on the face, forehead, chest, upper back and shoulders. Acne affects about 5.6 million Canadians, or nearly 20 per cent of the

population and causes emotional distress and can cause permanent scarring² or pigmentation changes.⁵ Acne affects about 90 per cent of adolescents and about 25 per cent of teens will still have acne at age 25.⁴

About ARAZLO™

ARAZLO tazarotene lotion, 0.045% w/w is a topical prescription indicated for the topical treatment of acne vulgaris. ARAZLO can be used on affected areas in patients 10 years and older. The safety and efficacy of ARAZLO in children below the age of 10 years has not been established.²

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit

www.bauschhealth.com

and connect with us on

[Twitter](#)

and

[LinkedIn](#)

Bausch Health, Canada Inc.'s prescription treatment portfolio is focused on dermatology -, gastrointestinal and cardio-metabolic conditions. Bausch Health also has two manufacturing facilities for prescription pharmaceuticals in Canada, in Laval, Quebec, and Steinbach, Manitoba. More information can be found at the Company's website at

www.bauschhealth.ca.

Forward-looking Statements

This news release may contain forward-looking statements about the future performance of Bausch Health which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.

Investor Contact:

Christina Cheng

ir@bauschhealth.com

(514) 856-3855

(877) 281-6642 (toll free)

Media Contact:

Kevin Wiggins

corporate.communications@bauschhealth.com

(908) 541-3785

REFERENCES**1. Quebec :**

https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/medicaments/tableau-nouveautes-innovateurs/tableau-nouveautes-innovateurs_2022-11-09.pdf
assessed Nov. 18, 2022

Ontario:

https://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/summary_edition43_20221024.pdf

Alberta:

https://idbl.ab.bluecross.ca/idbl/drugDetails?_cid=3ea4d70e-b206-466a-a30b-82746e11ed08&id=0000099458&intchg_grp_nbr=1&detailId=7661580

Saskatchewan:

<https://formulary.drugplan.ehealthsask.ca/Bulletins/Bulletin-0222-Nov-2022.pdf>

NIHB:

<https://nihb-ssna.express-scripts.ca/en/0205140506092019/16/160407>

2. ARAZLO (Tazarotene Lotion) Product Monograph, July 7, 2021.

3. "Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems." *Pharmaceutics*. Gemma Latter et al, October 2019, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835300/>, accessed Nov. 1, 2022.

4. Canadian Dermatology Association, Acne, Quick Facts, <https://dermatology.ca/public-patients/skin/acne/#:~:text=Acne%20affects%205.6%20million%20Canadians,adults%20ages%2020%20to%2040>, accessed Nov. 1, 2022.

5. "What to Know about Hyperpigmentation Acne." *Medical News Today*, Jessica Caporusio, April 28, 2021, <https://www.medicalnewstoday.com/articles/hyperpigmentation-acne>, accessed Nov. 1, 2022.

Investor Inquiries

ir@bauschhealth.com



LEGAL NOTICE

PRIVACY POLICY

877-281-6642
514-856-3855 (Canada)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

Use of this site signifies your agreement to
the [Legal Notice and Privacy Policy](#).

©2025 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION**

